Here, the selective CCR2 antagonist RS504393 that inhibits the infiltration of immunosuppressive MDSC into the TME in a bladder cancer mouse model (65) or CCL2 specific antibodies such as C1142 inhibiting tumor progression in a glioma model (66) might be interesting novel agents. Here, CCR2 is linked to glioma.